Poland · Delayed Price · Currency is PLN BioMaxima Statistics
Total Valuation
BioMaxima has a market cap or net worth of PLN 42.52 million. The enterprise value is 58.22 million.
| Market Cap | 42.52M |
| Enterprise Value | 58.22M |
Important Dates
The next confirmed earnings date is Wednesday, September 30, 2026.
| Earnings Date | Sep 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioMaxima has 4.19 million shares outstanding.
| Current Share Class | 4.19M |
| Shares Outstanding | 4.19M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 22.38% |
| Owned by Institutions (%) | n/a |
| Float | 2.91M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.71 |
| PB Ratio | 0.89 |
| P/TBV Ratio | 0.90 |
| P/FCF Ratio | 93.65 |
| P/OCF Ratio | 27.05 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 1.18, with an EV/FCF ratio of 128.24.
| EV / Earnings | n/a |
| EV / Sales | 0.97 |
| EV / EBITDA | 1.18 |
| EV / EBIT | 1.28 |
| EV / FCF | 128.24 |
Financial Position
The company has a current ratio of 1.39, with a Debt / Equity ratio of 0.34.
| Current Ratio | 1.39 |
| Quick Ratio | 0.66 |
| Debt / Equity | 0.34 |
| Debt / EBITDA | 0.33 |
| Debt / FCF | 35.52 |
| Interest Coverage | 40.74 |
Financial Efficiency
Return on equity (ROE) is -0.33% and return on invested capital (ROIC) is 1.33%.
| Return on Equity (ROE) | -0.33% |
| Return on Assets (ROA) | 0.57% |
| Return on Invested Capital (ROIC) | 1.33% |
| Return on Capital Employed (ROCE) | 77.06% |
| Weighted Average Cost of Capital (WACC) | 5.79% |
| Revenue Per Employee | 417,769 |
| Profits Per Employee | -1,091 |
| Employee Count | 143 |
| Asset Turnover | 0.75 |
| Inventory Turnover | 2.14 |
Taxes
In the past 12 months, BioMaxima has paid 54,000 in taxes.
| Income Tax | 54,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -26.79% in the last 52 weeks. The beta is 0.30, so BioMaxima's price volatility has been lower than the market average.
| Beta (5Y) | 0.30 |
| 52-Week Price Change | -26.79% |
| 50-Day Moving Average | 9.92 |
| 200-Day Moving Average | 11.69 |
| Relative Strength Index (RSI) | 67.97 |
| Average Volume (20 Days) | 2,344 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioMaxima had revenue of PLN 59.74 million and -156,000 in losses. Loss per share was -0.04.
| Revenue | 59.74M |
| Gross Profit | 28.68M |
| Operating Income | 727,000 |
| Pretax Income | -102,000 |
| Net Income | -156,000 |
| EBITDA | 49.39M |
| EBIT | 45.63M |
| Loss Per Share | -0.04 |
Balance Sheet
The company has 423,000 in cash and 16.12 million in debt, with a net cash position of -15.70 million or -3.74 per share.
| Cash & Cash Equivalents | 423,000 |
| Total Debt | 16.12M |
| Net Cash | -15.70M |
| Net Cash Per Share | -3.74 |
| Equity (Book Value) | 47.96M |
| Book Value Per Share | 11.44 |
| Working Capital | 7.96M |
Cash Flow
In the last 12 months, operating cash flow was 1.57 million and capital expenditures -1.12 million, giving a free cash flow of 454,000.
| Operating Cash Flow | 1.57M |
| Capital Expenditures | -1.12M |
| Depreciation & Amortization | 2.71M |
| Net Borrowing | -2.61M |
| Free Cash Flow | 454,000 |
| FCF Per Share | 0.11 |
Margins
Gross margin is 48.01%, with operating and profit margins of 1.22% and -0.26%.
| Gross Margin | 48.01% |
| Operating Margin | 1.22% |
| Pretax Margin | -0.17% |
| Profit Margin | -0.26% |
| EBITDA Margin | 82.68% |
| EBIT Margin | 76.37% |
| FCF Margin | 0.76% |
Dividends & Yields
BioMaxima does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -0.37% |
| FCF Yield | 1.07% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioMaxima has an Altman Z-Score of 2.51 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.51 |
| Piotroski F-Score | 5 |